Tuesday Sanofi Announced Riliprubart One-year Follow-Up From Phase 2 Study Showed Efficacy And Safety, And Rapid And Durable Reduction Of Key Biomarkers, Including Those Associated With Classical Complement Pathway And Nerve Cell Damage
Tuesday Sanofi Announced Riliprubart One-year Follow-Up From Phase 2 Study Showed Efficacy And Safety, And Rapid And Durable Reduction Of Key Biomarkers, Including Those Associated With Classical Complement Pathway And Nerve Cell Damage
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.